Does Aetna Cover Rehab?

Aetna operates as broad commercial network plus Medicaid-managed in specific states, with 22+ million covered across All 50 states; largest footprint in TX, FL, PA, NY, CA. Its parity compliance framework is enforced under MHPAEA; specific medical-necessity criteria must — under the 2024 Final Rule — be disclosed to plan participants upon request. The paragraphs that follow disaggregate the practical coverage framework.

Parity enforcement — what the 2024 rule changed

Aetna's parity compliance framework is governed federally through Department of Labor enforcement (for ERISA plans) and through state insurance commissioner oversight (for individual and small-group markets). On the empirical side, Aetna has been among the insurers more responsive to documented medical-necessity cases post-2024, though variation by plan product remains meaningful. The 2024 rule's operational consequences for Aetna include: (a) mandatory disclosure of medical-necessity criteria; (b) documented comparability analysis for NQTLs; (c) accelerated external-review pathways for denied behavioral-health claims.

Aetna plan types

The Aetna product portfolio — HMO, PPO, Open Access HMO/POS, EPO, Medicare Advantage — reflects differentiated benefit design by market segment (employer group, individual, Medicare, Medicaid-managed, military administration). Network adequacy assessments and medical-necessity criteria can vary meaningfully across these products. The Summary of Benefits and Coverage (SBC) document for the specific product should be the baseline reference for benefit verification.

A note on medication-assisted treatment

Medication-assisted treatment (MAT) coverage is a specific focus of the 2024 parity rule, which flagged restrictive MAT formulary tiering as a common parity violation. Aetna's MAT coverage: covers buprenorphine (generic preferred) and Vivitrol; Sublocade occasionally needs prior authorization. Plan participants should verify formulary tier, prior-authorization requirements, and step-therapy protocols for specific MAT medications (buprenorphine-naloxone, methadone via OTP, extended-release naltrexone, extended-release buprenorphine) prior to treatment initiation.

When Aetna denies — appeal playbook

Appeal strategy for Aetna denials should focus on three documents: (1) the specific medical-necessity criteria applied in the denial (disclosable under 2024 parity rule on request within 10 business days); (2) the comparative analysis Aetna produced demonstrating parity compliance for the non-quantitative treatment limit in question; (3) an ASAM 4e-aligned clinical assessment from an independent treating clinician. Appeals that cite specific criteria against specific clinical documentation have substantially higher reversal rates than appeals that argue clinical judgment in general terms.

Before admission

The operational prerequisites for a Aetna admission are: (a) confirmed in-network status for the specific product (HMO/PPO/etc.); (b) documented prior authorization with specific day-count authorized; (c) written Verification of Benefits from the facility; (d) current formulary review for any MAT medication. Proceeding on verbal confirmation alone is a common source of cost-sharing disputes at claim adjudication.